On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Weekly Release  2003: Volume 7/ Issue 2 Article 1
Back to Table of Contents

Eurosurveillance, Volume 7, Issue 2, 09 January 2003

Citation style for this article: Editorial team. Heightened health security concern following ricin alert in the United Kingdom. Euro Surveill. 2003;7(2):pii=2143. Available online:

Heightened health security concern following ricin alert in the United Kingdom

Editorial team (, Eurosurveillance editorial office.

On 7 January the Metropolitan Police and the English Department of Health’s Deputy Chief Medical Officer (CMO) made a joint statement (1) informing the public that seven people had been arrested in London on 5 January under the Terrorism Act 2000 ( On 7 January material found in a residential premises tested positive for the presence of ricin poison after analysis at the Defence Science and Technology Laboratories at Porton Down in southwest England. The United Kingdom (UK) is believed to be a possible target for bioterrorist activities, and so because of concern for the safety of the public, the police are working closely with the English Department of Health. 

The early stages of ricin intoxication are difficult to distinguish from those of some infections, and may mimic septicaemia, and so it was particularly important that healthcare workers in the UK be alerted of the possibility of ricin poisoning. A letter was cascaded via fax and email for immediate distribution from the Deputy CMO to all members of the National Health Service on 7 January. This included the text of the joint statement, and contact details for the National Poisons Information Service and the Public Health Laboratory Service (PHLS).

The PHLS made the joint statement available on its website, with links to interim guidance for the investigation and management of outbreaks and incidents of unusual illness, ricin guidelines (2), and information on other chemicals which could be used for deliberate release. On 9 January, interim guidelines for health professionals dealing with suspect packages and materials were posted on the website (3).

A toxalbumin extracted from the beans of the castor oil plant, ricin inhibits protein synthesis, which causes cell death. Death may be due to multi-organ failure. The onset of symptoms may be delayed for several hours after exposure (which may be via ingestion, inhalation or injection), and can include irritation, gastroenteritis, conjunctivitis, respiratory symptoms, seizures and CNS depression, fluid loss leading to tachycardia, allergic reactions, abnormal liver functions, and haematuria, proteinuria and elevated creatinine.

There is no known antidote for ricin, and treatment is symptomatic and supportive only. In the event of mass exposure to ricin, careful decontamination of patients is recommended. More detailed information is available in reference 2.

Ricin is considered to be one of the chemical warfare options available to bioterrorists if used in aerosols or injected. In 1977 a Bulgarian political dissident living in London died after being fired at or injected with a ricin filled bullet (


References :
  1. Department of Health [England]. Joint statement from the Metropolitan Police and the Deputy Chief Medical Officer. Press release 2003/0008. 7 January 2003. (
  2. Department of Health [England]. Ricin guidelines. Version 1.1, amended 12 December 2002. ( [accessed 9 January 2003]
  3. Responding to suspect packages and materials – actions to be taken. Interim guidelines for health professionals dealing with suspected packages and materials. Version 1: Issue date 8 January 2003. (

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.